S.Korea’s GC Cell targets global cell therapy CDMO business
GC Cell Corp., an affiliate of South Korea’s major pharmaceutical company GC Biopharma Corp., is targeting the cell therapy contract developme...
Celltrion’s Vegzelma listed on US PBM preferred drug list
South Korea's Celltrion Healthcare Co. announced on Tuesday that its anti-cancer biosimilar Vegzelma (active ingredient: bevacizumab) was listed as ...
Celltrion Healthcare's Herzuma selected as funded brand in NZ
Celltrion Healthcare Co. announced on Thursday that its biosimilar anticancer drug Herzuma (active ingredient trastuzumab) for breast and gastr...
Cytogen, Japan NCCH collaborate on cancer research
South Korea's Cytogen, Inc. announced on Monday it will start cancer research using circulating tumor cells (CTC) with the National Cancer Center Ho...
South Korean bio, pharma industry set to take leap
South Korea’s chemical maker LG Chem Ltd. is expected to reap more than 1 trillion won ($768.5 million) in sales this year from its new growth...
Lunit gets FDA approval for AI cancer diagnosis solution
South Korean medical AI company Lunit said on Tuesday its Lunit Insight DBT, an AI imaging diagnosis solution aiding in breast cancer diagnosis, has...
'World-class bispecific antibody technology of ABL Bio'
MADRID - "The clinical Phase 1 results of the immune-oncology candidate ABL111, developed in collaboration with ABL Bio, have been selected as the b...
Lunit participates in US gov't Cancer Moonshot
South Korea's medical AI company Lunit announced on Friday it will participate in the US President Joe Biden's cancer-conquering project Cancer Moon...
Gencurix gets FDA OK for breast cancer prognosis analysis device
South Korean biotech company Gencurix Inc. announced on Wednesday its subsidiary GenoBio has received approval from the US Food and Drug Admini...
SK Telecom invests in AI startups Allganize, Imprimed
SK Telecom Co. has invested a combined 9.4 billion won ($7.2 million) in artificial intelligence startups Allganize Inc. and Imprimed Inc., the top ...
VaxCell-Bio applies for approval of anti-cancer drug for dogs
South Korea’s VaxCell Biotherapeutics Co. (VaxCell-Bio) on Tuesday announced its application for approval for Vaxleukin-15, an anti-cancer dru...
Curocell to localize blood cancer drug by 2025
South Korean biotech company Curocell Inc. on Sunday said it will apply for approval from the Ministry of Food and Drug Safety in September next yea...
HLB gets global rights to Chinese liver cancer drug
South Korea’s HLB Therapeutics Co. on Tuesday said its US subsidiary Elevar Therapeutics has acquired the global rights excluding South Kore...
Noul releases AI-based diagnostic gizmo for cervical cancer
Noul Co., a South Korean company specializing in artificial intelligence (AI)-based blood and cancer diagnostic platforms, has entered the cancer di...
NGeneBio joins US gov't Cancer Moonshot project
South Korean medical diagnostic company NGeneBio Co. announced on Tuesday it joins US President Joe Biden's cancer-conquering project "Cancer Moonsh...
Genome & Co.’s bile duct cancer drug candidate enters Phase 2 trials
Genome & Company, a South Korean developer of microbiome-based drugs, on Tuesday said its GEN-001, a leading immunotherapy drug candidate for bi...
VaxCell Bio's treatment shows promise for advanced liver cancer
South Korea's VaxCell Biotherapeutics Co. on Tuesday said its treatment for advanced liver cancer under development stopped or greatly reduced the g...
S.Korea’s Coreline Soft teams up with HCK of Switzerland
South Korea's Coreline Soft, a maker of artificial intelligence (AI)-based imaging diagnostic materials, on Wednesday said it will sell its chest di...
Gencurix supplies companion diagnostic kits to cancer center in India
South Korean biotech company Gencurix Inc. on Friday said it started supplying its companion diagnostic test Droplex to a national cancer center in ...
S.Korea's Qurient, US National Cancer Institute to develop anti-cancer drug
South Korea's Qurient Co. announced on Monday that it signed a research and development agreement with the US government agency National Cancer Inst...
Gencurix joins US gov't Cancer Moonshot project
South Korean cancer molecular diagnostics company Gencurix Inc. announced on Monday that it joins US President Joe Biden's cancer-conquering project...
Boryung Pharma's sales surpass $311 mn in H1 2023
South Korea’s Boryung Corp. has alleviated the fear of falling behind in its sector expressed by its third-generation chairman Jay Kim Jung-Gy...
Lunit to supply AI diagnosis solution to Saudi's medical institution
South Korea's medical AI company Lunit announced on Wednesday that it has signed a contract to supply its artificial intelligence (AI) solution for ...
S.Korea's NGeneBio establishes US corporation NGeneBioAI
South Korean medical diagnostic company NGeneBio Co. announced on Monday that it has established an artificial intelligence (AI) precision diagnosti...
Clinomics releases equipment that quickly finds lung cancer mutations
Clinomics, a South Korean biotech company specializing in liquid biopsies, on Thursday said it developed equipment that can detect four types of l...
Novomics expands presence in Chinese cancer market
South Korean molecular diagnostics company Novomics Co. announced on Wednesday that it has signed a collaboration agreement with Chinese molecular d...
Prestige Biopharma participates in US gov’t Cancer Moonshot
Prestige Biopharma, a Singapore-based biopharmaceutical company with operations in South Korea and the US, announced on Tuesday that it will partici...
Celltrion applies for approval in US for eye treatment biosimilar
South Korean biopharmaceutical company Celltrion Inc. on Friday said it applied for approval from the US Food and Drug Administration (FDA) for CT-P...
LegoChem Bio receives FDA approval for phase 1,2 trials of LCB84
South Korean pharmaceutical firm LegoChem Biosciences Inc. announced on Thursday that it has received approval from the US Food and Drug Administrat...
HLB submits new drug application to FDA for Rivoceranib liver cancer drug
HLB Co. announced on May 17 that it has submitted a new drug application (NDA) to the US Food and Drug Administration (FDA) for the approval of Rivo...
